Trial Profile
Escitalopram for Agitation in Alzheimer's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Therapeutic Use
- Acronyms S-CitAD
- 28 Feb 2024 Planned primary completion date changed from 1 May 2024 to 1 Mar 2024.
- 28 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2023 Planned End Date changed from 1 Aug 2024 to 1 May 2025.